Legend Biotech (LEGN) has released an update.
Legend Biotech’s revenues soared in the third quarter of 2024, driven by the impressive sales growth of their cell therapy, CARVYKTI®, which achieved a remarkable 87.6% year-over-year increase. The company expanded its commercial production capabilities in Belgium and launched new operations in Switzerland, bolstering its global reach. With a strong cash position of $1.2 billion, Legend Biotech continues to solidify its leadership in cell therapy innovation.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.
